ABL Bio Inc Cash Flow Conversion Efficiency

Latest as of June 2026: -0.135x

ABL Bio Inc cash flow conversion efficiency. Based on the latest financial reports, ABL Bio Inc (298380) has a cash flow conversion efficiency ratio of -0.135x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-23.42 Billion ≈ $-15.87 Million USD) by net assets (₩173.94 Billion ≈ $117.88 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of ABL Bio Inc (2016–2025)

Cash flow conversion efficiency of ABL Bio Inc from 2016 to 2025. This chart illustrates how ABL Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 298380 live share price for real-time trading data and today's change.

ABL Bio Inc Cash Flow Conversion Ratio Explained

ABL Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

ABL Bio Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of ABL Bio Inc ranked by their cash flow conversion efficiency. Also see market cap of ABL Bio Inc for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Guangdong Jia Yuan Technology Co Ltd SHG:688388	0.006x
Mobileye Global Inc. Class A Common Stock NASDAQ:MBLY	0.016x
Staidson Beijing Biopharma SHE:300204	-0.049x
Vertex NASDAQ:VERX	0.140x
Chongqing Zaisheng Tech Corp SHG:603601	0.066x
Quantum Computing Inc NASDAQ:QUBT	-0.007x
Browave TWO:3163	-0.034x
Sino Horizon Holdings Ltd TW:2923	-0.028x

Annual Cash Flow Conversion Efficiency for ABL Bio Inc (2016–2025)

The table below shows the annual cash flow conversion efficiency of ABL Bio Inc from 2016 to 2025. Review 298380 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩156.70 Billion ≈ $106.19 Million	₩-41.25 Billion ≈ $-27.96 Million	-0.263x	+36.55%
2024-12-31	₩167.28 Billion ≈ $113.36 Million	₩-69.40 Billion ≈ $-47.03 Million	-0.415x	-8.37%
2023-12-31	₩74.08 Billion ≈ $50.20 Million	₩-28.36 Billion ≈ $-19.22 Million	-0.383x	-136.90%
2022-12-31	₩69.51 Billion ≈ $47.11 Million	₩72.13 Billion ≈ $48.88 Million	1.038x	+242.99%
2021-12-31	₩55.95 Billion ≈ $37.92 Million	₩-40.61 Billion ≈ $-27.52 Million	-0.726x	-39.12%
2020-12-31	₩90.66 Billion ≈ $61.44 Million	₩-47.29 Billion ≈ $-32.05 Million	-0.522x	-188.67%
2019-12-31	₩132.01 Billion ≈ $89.46 Million	₩-23.86 Billion ≈ $-16.17 Million	-0.181x	-123.90%
2018-12-31	₩156.96 Billion ≈ $106.37 Million	₩-12.67 Billion ≈ $-8.59 Million	-0.081x	-197.13%
2017-12-31	₩-85.96 Billion ≈ $-58.25 Million	₩-7.14 Billion ≈ $-4.84 Million	0.083x	-67.72%
2016-12-31	₩-12.10 Billion ≈ $-8.20 Million	₩-3.12 Billion ≈ $-2.11 Million	0.257x	--

About ABL Bio Inc

KQ:298380 Korea Biotechnology

Market Cap

$1.42 Billion

₩2.10 Trillion KRW

Market Cap Rank

#7225 Global

#169 in Korea

Share Price

₩37450.00

Change (1 day)

+5.20%

52-Week Range

₩35600.00 - ₩245500.00

All Time High

₩245500.00